Becton Dickinson Lowers Annual Profit Forecast After Completing Sale of Biosciences Unit
Becton Dickinson cut its 2026 profit outlook on Monday following the sale of its biosciences unit. The company also missed quarterly earnings expectations.
Insights:
Becton, Dickinson and Company , also known as Becton Dickinson (BD), announced on Monday that it has reduced its adjusted earnings-per-share guidance for fiscal year 2026 to a range of $12.35–$12.65. The revision directly reflects the completed separation and sale of the Becton Dickinson biosciences and diagnostics unit (life sciences business) to Waters Corporation . Following the announcement of the updated outlook and the transaction's completion, shares of Becton Dickinson fell nearly 5% in immediate market reaction.
The transaction, which was reported as closing immediately on Monday, involves a significant reallocation of corporate overhead and proceeds. The financial adjustment to the fiscal 2026 guidance accounts for the shift of costs and income related to corporate overhead and transition services from Becton Dickinson to Waters Corporation. This movement of financial responsibilities and the associated transition-service income are primary factors in the altered near-term earnings outlook for the medical technology firm.
